Challenges in acute ischemic stroke clinical trials

Current Cardiology Reports

Volumn 14, Issue 6, 2012, Pages 761-766

  Furlan, Anthony J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Acute ischemic stroke; Clinical trials; Neuroprotectant; Reperfusion; STAIR; Tissue plasminogen activator; tPA

Indexed keywords

ALTEPLASE; PLACEBO;

ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; DRUG EFFICACY; HUMAN; NEUROIMAGING; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); STROKE PATIENT; THROMBECTOMY;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPERFUSION; STROKE; THROMBECTOMY; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 84870571173     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0311-9     Document Type: Article

References (21)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-7.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, for the ECASS Investigators, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-29.
3. Furlan AJ, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA. 1999;282:2003-11.
4. The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 hours of acute ischemic stroke (the third international stroke trial IST-3): a randomized controlled trial. Lancet. 2012. doi:101016/S0140-6736(12)60768-5. Published online
5. IMS3 A Descriptive Study of Interventional Management of Stroke III Trial Investigator recruitment enhancement strategies. Stroke. 2012;43:A3192.
6. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467.
7. The GUSTO Investigators. An international randomized trial comparing 4 thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-82.
8. Muir KW. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke. 2002;33:1545-50.
9. Furlan AJ, Acute Stroke Trials. Strengthening the underpowered. Stroke. 2002;33:1450-1.
10. Fisher M. New approaches to neuroprotective drug development. Stroke. 2011;42 Suppl 1:S24-7.
11. Donnan GA. A new road map for neuroprotection. Stroke. 2008;39:242-8.
12. Furlan AJ, Fisher M. Devices, drugs, and the Food and Drug Administration: increasing implications for ischemic stroke. Stroke. 2005;36:398-9.
13. Furlan AJ. Ethics and feasibility of placebo-controlled interventional acute stroke trials. Stroke. 2009:e533-4.
14. Donnan GA, Davis SM. The ethics of thrombolytic trials beyond 3 (or 4.5) hours. Randomized controlled trials are required to change clinical practice. Stroke. 2009;40:1545.
15. Stroke Therapy Academic Industry Roundtable (Fisher M, Chair). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752-8.
16. Stroke Therapy Academic Industry Roundtable (Fisher M, Chair). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke. 2001;32:1598-606.
17. Fisher M. Recommendations for advancing development of acute stroke therapies. for the Stroke Therapy Academic Industry Roundtable. Stroke. 2003;34:1539-46.
18. Fisher M. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry Roundtable. Stroke. 2005;36:1808-13.
19. Fisher M, Hanley DF, Howard G, Jauch EC, Warach S. Recommendations from STAIR V meeting on acute stroke trials, technology, and outcomes. Stroke. 2007;38:245-8.
20. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke. 2009;40:2594-600.
21. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, et al. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial, and neuroprotective therapies. Stroke. 2011;42:2645-50.